PMID- 25284747
OWN - NLM
STAT- MEDLINE
DCOM- 20160607
LR  - 20181202
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 68
IP  - 12
DP  - 2014 Dec
TI  - Persistence with solifenacin add-on therapy in men with benign prostate 
      obstruction and residual symptoms of overactive bladder after tamsulosin 
      monotherapy.
PG  - 1496-502
LID - 10.1111/ijcp.12483 [doi]
AB  - AIMS: In spite of the reported efficacy and safety of antimuscarinics in men with 
      OAB (overactive bladder) and BPO (benign prostatic obstruction), many patients do 
      not persist with the treatment. We aimed to evaluate persistence and the reasons 
      for the discontinuation of solifenacin add-on therapy in men with residual 
      symptoms of OAB after tamsulosin monotherapy for BPO in a real clinical 
      environment. METHODS: Men aged >/= 45 years with IPSS >/= 12 and symptoms of OAB 
      (OAB-V8 >/= 8, micturition >/= 8/24 h, urgency >/= 2/24 h) were prescribed tamsulosin 
      0.2 mg. After 4 weeks, men who had residual symptoms of OAB (OAB-V8 >/= 8, 
      micturition >/= 8/24 h, urgency >/= 1/24 h) and reported that they were 
      'dissatisfied' or 'a little satisfied' with the therapy were enrolled and 
      prescribed solifenacin 5 mg in combination with tamsulosin. After 52 weeks, 
      persistence and the reasons for the discontinuation of solifenacin were 
      evaluated. Factors related to persistence were analysed. RESULTS: Of the 305 men 
      who had been treated with tamsulosin, 176 were prescribed solifenacin. After 52 
      weeks, 44 (25%) remained on solifenacin therapy. Of the 132 who discontinued 
      solifenacin, 85 were evaluated on the reason for discontinuation. The three most 
      common reasons for discontinuation were adverse events (AEs) (35%), lack of 
      efficacy (33%), and improvement in symptoms (16%). The aggravation of voiding 
      symptoms was the most common AE leading to discontinuation. Retention was 
      observed in 11 men. None of the demographical or clinical characteristics were 
      significantly related to persistence. CONCLUSIONS: Only 25% men with OAB and BPO 
      remained on antimuscarinic add-on therapy after 1 year, mostly because of AEs and 
      lack of efficacy. Realistic data should be added to what is already known about 
      antimuscarinic treatment in men by including patients who were excluded or who 
      dropped out of well-designed clinical trials.
CI  - (c) 2014 John Wiley & Sons Ltd.
FAU - Lee, Y-S
AU  - Lee YS
AD  - Department of Urology, Samsung Changwon Hospital, Sungkyunkwan University School 
      of Medicine, Changwon, Korea.
FAU - Lee, K-S
AU  - Lee KS
FAU - Kim, J C
AU  - Kim JC
FAU - Hong, S
AU  - Hong S
FAU - Chung, B H
AU  - Chung BH
FAU - Kim, C-S
AU  - Kim CS
FAU - Lee, J G
AU  - Lee JG
FAU - Kim, D K
AU  - Kim DK
FAU - Park, C H
AU  - Park CH
FAU - Park, J K
AU  - Park JK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141006
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Muscarinic Antagonists)
RN  - 0 (Quinuclidines)
RN  - 0 (Sulfonamides)
RN  - 0 (Tetrahydroisoquinolines)
RN  - G3P28OML5I (Tamsulosin)
RN  - KKA5DLD701 (Solifenacin Succinate)
SB  - IM
MH  - *Drug Therapy, Combination
MH  - Humans
MH  - Male
MH  - Muscarinic Antagonists/adverse effects/*therapeutic use
MH  - Prostatic Hyperplasia/*drug therapy
MH  - Quinuclidines/administration & dosage
MH  - Solifenacin Succinate/pharmacology/therapeutic use
MH  - Sulfonamides/pharmacology/therapeutic use
MH  - Tamsulosin
MH  - Tetrahydroisoquinolines/administration & dosage
MH  - Urinary Bladder, Overactive/*drug therapy
EDAT- 2014/10/07 06:00
MHDA- 2016/06/09 06:00
CRDT- 2014/10/07 06:00
PHST- 2014/10/07 06:00 [entrez]
PHST- 2014/10/07 06:00 [pubmed]
PHST- 2016/06/09 06:00 [medline]
AID - 10.1111/ijcp.12483 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2014 Dec;68(12):1496-502. doi: 10.1111/ijcp.12483. Epub 2014 
      Oct 6.